Related Experiment Videos
Multiple sclerosis, interferon beta and clinical thyroid dysfunction.
A Kreisler1, J de Seze, T Stojkovic
1Department of Neurology, Lille University Hospital, France.
Acta Neurologica Scandinavica
|February 13, 2003
Summary
Interferon beta (IFN-beta) treatment for multiple sclerosis can cause clinical thyroid dysfunction, though it is rare. This side effect, including hyperthyroidism and hypothyroidism, can be severe and requires monitoring.
Area of Science:
- Neurology
- Endocrinology
- Immunology
Background:
- Interferon beta (IFN-beta) is a common treatment for multiple sclerosis (MS).
- Thyroid dysfunction is a potential adverse effect of various medications.
Observation:
- This study analyzed 700 patients with MS treated with IFN-beta.
- Clinical thyroid dysfunction was observed in a small subset of patients.
Findings:
- Five patients on IFN-beta1b developed hyperthyroidism; three required treatment cessation.
- Two patients on IFN-beta1a developed hypothyroidism, one requiring thyroid hormone replacement.
- One patient on IFN-beta1a showed increased thyroid volume without hormonal changes.
Implications:
- Clinical thyroid dysfunction is a rare but significant side effect of IFN-beta therapy in MS patients.
- Monitoring thyroid function is crucial for patients undergoing IFN-beta treatment.
- The severity of thyroid dysfunction necessitates careful patient management and potential treatment adjustments.